<p>Comparative Effects of Curcumin versus Nano-Curcumin on Insulin Resistance, Serum Levels of Apelin and Lipid Profile in Type 2 Diabetic Rats</p>

Abstract

Background and Purpose: Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance and abnormalities in insulin production. Apelin is associated with insulin resistance. According to the anti-diabetic properties of curcumin, the purpose of this study was to compare the effects of curcumin and nano-curcumin intake on insulin resistance and serum levels of fasting blood sugar (FBS), Apelin, and lipid profile (cholesterol, triglyceride, LDL, HDL and VLDL) in T2DM rats. Materials and Methods: Forty-eight male Wistar rats were divided into six groups: Control, diabetic, diabetic treated with two doses of curcumin (100 and 200 mg/kg) and diabetic treated with two doses of nano-curcumin (100 and 200 mg/kg). Induction of T2DM was performed by intraperitoneal injection of Nicotinamide (110 mg/kg) and Streptozotocin (45 mg/kg) in the fasting state. Rats received different doses of nano-curcumin and curcumin by gavage (daily) for 28 days. At the end of the intervention period, insulin resistance and serum levels of FBS, apelin and lipid profiles were measured. Results: Insulin resistance and serum levels of FBS, Apelin, cholesterol, triglycerides, LDL, and VLDL were significantly decreased in diabetic rats treated with curcumin and nanocurcumin (p<0.05) so that nano-curcumin in reducing lipid profile is more effective than curcumin (P<0.05). Serum level of HDL in nano-curcumin groups was significantly higher than diabetic and curcumin groups (p<0.05). Also, with increasing insulin resistance, serum level of apelin increased (P<0.05). Conclusion: The therapeutic effects of curcumin and nano-curcumin were effective in decreasing insulin resistance, serum levels of FBS, apelin and lipid profile. The dose of 100 mg/kg nano-curcumin was more effective in reducing lipid profile.

Adipokines, Myokines, and Cardiokines: The Role of Nutritional Interventions

“…Moreover, experimental studies have proved potential therapeutic actions of polyphenol compounds on APLN levels: curcumin supplementation mitigates APLN abnormalities in diabetic rats and in obese patients [130] (Table 4).…”

The effects of nano‐curcumin supplementation on glycemic control, blood pressure, lipid profile, and insulin resistance in patients with the metabolic syndrome: A randomized, double‐blind clinical trial

“…The results of this study showed that using 100 mg/kg of nano‐curcumin is more effective than 200 mg/kg, however, using 200 mg/kg body weight curcumin had more therapeutic effect. These findings are helpful for future studies (Shamsi‐Goushki et al, 2020).…”

Curcumin Nanoparticles as Promising Therapeutic Agents for Drug Targets

“…In the case of each subject of the group receiving nanocurcumin treatment, it was seen that after the treatment, the level of total cholesterol, triglyceride, LDL-C, and HDL-C was substantially reduced in the serum level than that of before treatment. Shamsi et al studied the impact of various doses of nanocurcumin on the level of lipid profile present in the blood serum [ 64 ]. It was found in the study that the cholesterol, low density lipoprotein, very low-density lipoprotein, as well as triglyceride level in the serum of the diabetic rats were reduced to a great extent.…”